Conference Report

Update on HIV Pharmacology From the 2007 Budapest Meeting

Source: CCO Independent Conference Coverage of the 2007 International Workshop on Clinical Pharmacology of HIV Therapy*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on HIV Pharmacology From the 2007 Budapest Meeting

Faculty:
David J. Back, PhD Courtney V. Fletcher, PharmD

CME CREDIT INFORMATION

Release Date: 06/08/07

Expiration Date: 06/07/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the data from studies designed to determine the optimal dose of ritonavir when combined with elvitegravir
Recall the recommended dosing strategy for maraviroc when combined with darunavir/ritonavir
Detail the data from studies that investigated the use of boosted PIs in patients with organ dysfunction
Describe new genetic insights into abacavir hypersensitivity

Topics covered include:

Introduction
Boosting Elvitegravir With Ritonavir
Vicriviroc Clinical Breakpoints
Darunavir/Ritonavir Increases Maraviroc Concentrations
Pravastatin and Darunavir/Ritonavir Interactions
Liver Impairment and Boosted PI Pharmacokinetics
Atazanavir Pharmacokinetics and Renal Impairment
TDM and Atazanavir Concentration
Potential Tipranavir/Ritonavir Interactions
PI “Forgiveness”
Differing PI Effects on Ritonavir Pharmacokinetics
Efavirenz Pharmacokinetics in a Pediatric Cohort
Intracellular Levels With Once- vs Twice-Daily Abacavir
Genetic Insights Into Abacavir Hypersensitivity

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.